Inclusion Criteria:
1. Nephrotic syndrome Group:
* Age between 18-70 years old
* Diagnosed with nephrotic syndrome: proteinuria≥3.5 g/24h or morning urine protein/creatinine ratio ≥3.0g/g), with serum albumin \<30g/L present at the time of enrollment, with or without edema or hyperlipidemia
* Calculated creatinine clearance (CrCl) \>50ml/min using the Cockcroft-Gault formula
* Actual body weight \>60kg, and body mass index within the range of 18.5-28kg/m2
* Signed informed consent form
2. Healthy volunteer Group:
* Age between 18-70 years old
* Serum albumin ≥40g/L
* Calculated CrCl \>50ml/min using the Cockcroft-Gault formula
* Actual body weight \>60kg, and body mass index within the range of 18.5-28kg/m2
* Signed informed consent form
Exclusion Criteria:
* Serun albumin \<30 g/L for other reasons in patients with nephrotic syndrome as judged by the investigator
* Prolonged PT, INR, APTT at baseline (defined as greater than the upper limit of normal values)
* Platelet count \<100×109/L or ≥300×109/L due to hematological diseases confirmed by laboratory tests
* History of: gastrointestinal bleeding, intracranial hemorrhage, hemoptysis, or other clinically documented bleeding from internal organs within the last 3 months; surgery (except \>3 days after renal biopsy without bleeding complications) or trauma. Bleeding complications after renal biopsy are defined as: ① bleeding (hematuria, perirenal hematoma, or arteriovenous fistula) that occur after renal biopsy requiring transfusion, resulting in altered hemodynamics, or requiring surgery or interventional treatment; ② symptomatic perirenal hematoma; and ③visible hematuria that persist for \>3 days postoperatively.
* A lesion or condition with a significant risk of major bleeding, such as current or recent gastrointestinal ulcer, malignant tumors with a high risk of bleeding, esophageal varices, arteriovenous malformations, vascular aneurysms, or major intravertebral or intracerebral vascular malformations.
* Serious bleeding disorders as judged by the investigator
* Systemic lupus erythematosus with or without renal damage
* Bleeding or thrombophilia disorders as judged by the investigator
* History of stroke
* History of congestive heart failure (New York grade II or above) at the time of screening
* Liver dysfunction (cirrhosis or bilirubin \>2×, and serum transaminases \>3×, upper limit of normal)
* Use of (but not limited to) the prescription medications that are inhibitors or inducers of CYP3A4 and/or P-gp within the past 14 days:
* CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, etc.) ②CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin, etc.)
* P-gp inducers (e.g., apalutamide, rifampicin, etc.) ④ P-gp inhibitors (e.g., dronedarone, cyclosporine, erythromycin, ketoconazole, quinidine, verapamil, amiodarone, etc.) ⑤Selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI)
* Use of antiplatelet and/ or anticoagulant agents within 5 half-lives (at least 7 days): including but not limited to heparin, heparin derivatives, aspirin, clopidogrel, prasugrel, nonsteroidal anti-inflammatory drugs, warfarin, rivaroxaban, dabigatran, apixaban, etc.
* Pregnant or breastfeeding women or women of childbearing age without contraception
* Uncontrolled severe hypertension (SBP≥180mmHg, DBP≥110mmHg)
* Conditions considered unsuitable for inclusion in this study, judged by investigator
* Patients with hypersensitivity to the active ingredient or other excipients of the Edoxaban and enoxaparin sodium
* History of immune-mediated heparin-induced thrombocytopenia (HIT) or presence of circulating antibodies within the previous 100 days.
* Spinal or epidural anesthesia or local anesthesia within 24 hours prior to the administration of enoxaparin sodium and Edoxaban
